Investor Overview

Stock Information
Loading data...
Press Releases
Nov 22, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that it has successfully extended the cumulative net sales covenant timing of its April 2020 Securities Purchase and Security Agreement to...

Nov 19, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will participate in a fireside chat and host one-on-one meetings at the Piper Sandler 33rd...

Nov 15, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and nine-month periods ended September 30, 2021. "We are extremely excited by...

Nov 10, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that it has submitted the registration for its hormone-free contraceptive vaginal gel to the Mexican Regulatory Agency COFEPRIS (Comisión...

Nov 4, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will participate in the Stifel 2021 Virtual Healthcare Conference as follows: Date Tuesday,...

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. 

The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com.  

The Company is evaluating its investigational drug candidate EVO100 for the prevention of chlamydia and gonorrhea in women in a pivotal Phase 3 clinical trial, EVOGUARD. Top-line results are expected in the third quarter of 2022 and assuming positive results Evofem plans to file an sNDA in the first quarter of 2023.

The addressable U.S. market opportunity for these current and investigational indications is estimated at $3.6 - $4.5 billion in aggregate.  

Evofem intends to expand Phexxi’s global reach and further increase its commercial potential through ex-U.S. licenses. Discussions are underway with potential licensees for commercialization of Phexxi in multiple international markets.

Latest Financial Results

Q2 2021, Ended June 30, 2021

Earnings Release
Earnings Call
10-Q Filing
XBRL